Taiwan
· Delayed Price · Currency is TWD SCI Pharmtech Statistics
Total Valuation
SCI Pharmtech has a market cap or net worth of TWD 7.97 billion. The enterprise value is 8.42 billion.
| Market Cap | 7.97B |
| Enterprise Value | 8.42B |
Important Dates
The next estimated earnings date is Friday, August 8, 2025.
| Earnings Date | Aug 8, 2025 |
| Ex-Dividend Date | Jul 1, 2025 |
Share Statistics
SCI Pharmtech has 119.51 million shares outstanding. The number of shares has increased by 6.49% in one year.
| Current Share Class | 119.51M |
| Shares Outstanding | 119.51M |
| Shares Change (YoY) | +6.49% |
| Shares Change (QoQ) | -0.16% |
| Owned by Insiders (%) | 5.40% |
| Owned by Institutions (%) | 0.54% |
| Float | 69.80M |
Valuation Ratios
The trailing PE ratio is 15.33.
| PE Ratio | 15.33 |
| Forward PE | n/a |
| PS Ratio | 5.06 |
| PB Ratio | 1.44 |
| P/TBV Ratio | 1.45 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | 9.37 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 20.88, with an EV/FCF ratio of -39.70.
| EV / Earnings | 16.13 |
| EV / Sales | 5.35 |
| EV / EBITDA | 20.88 |
| EV / EBIT | 53.18 |
| EV / FCF | -39.70 |
Financial Position
The company has a current ratio of 1.53, with a Debt / Equity ratio of 0.17.
| Current Ratio | 1.53 |
| Quick Ratio | 0.81 |
| Debt / Equity | 0.17 |
| Debt / EBITDA | 2.21 |
| Debt / FCF | -4.52 |
| Interest Coverage | 38.34 |
Financial Efficiency
Return on equity (ROE) is 9.77% and return on invested capital (ROIC) is 1.85%.
| Return on Equity (ROE) | 9.77% |
| Return on Assets (ROA) | 1.70% |
| Return on Invested Capital (ROIC) | 1.85% |
| Return on Capital Employed (ROCE) | 3.05% |
| Revenue Per Employee | 6.59M |
| Profits Per Employee | 2.18M |
| Employee Count | 239 |
| Asset Turnover | 0.23 |
| Inventory Turnover | 1.96 |
Taxes
In the past 12 months, SCI Pharmtech has paid 108.54 million in taxes.
| Income Tax | 108.54M |
| Effective Tax Rate | 17.22% |
Stock Price Statistics
The stock price has decreased by -26.54% in the last 52 weeks. The beta is -0.10, so SCI Pharmtech's price volatility has been lower than the market average.
| Beta (5Y) | -0.10 |
| 52-Week Price Change | -26.54% |
| 50-Day Moving Average | 69.77 |
| 200-Day Moving Average | 83.83 |
| Relative Strength Index (RSI) | 33.72 |
| Average Volume (20 Days) | 97,205 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, SCI Pharmtech had revenue of TWD 1.57 billion and earned 521.91 million in profits. Earnings per share was 4.35.
| Revenue | 1.57B |
| Gross Profit | 397.95M |
| Operating Income | 187.58M |
| Pretax Income | 630.44M |
| Net Income | 521.91M |
| EBITDA | 429.91M |
| EBIT | 187.58M |
| Earnings Per Share (EPS) | 4.35 |
Balance Sheet
The company has 511.43 million in cash and 957.29 million in debt, giving a net cash position of -445.87 million or -3.73 per share.
| Cash & Cash Equivalents | 511.43M |
| Total Debt | 957.29M |
| Net Cash | -445.87M |
| Net Cash Per Share | -3.73 |
| Equity (Book Value) | 5.54B |
| Book Value Per Share | 46.33 |
| Working Capital | 492.22M |
Cash Flow
In the last 12 months, operating cash flow was 850.69 million and capital expenditures -1.06 billion, giving a free cash flow of -212.00 million.
| Operating Cash Flow | 850.69M |
| Capital Expenditures | -1.06B |
| Free Cash Flow | -212.00M |
| FCF Per Share | -1.77 |
Margins
Gross margin is 25.28%, with operating and profit margins of 11.92% and 33.15%.
| Gross Margin | 25.28% |
| Operating Margin | 11.92% |
| Pretax Margin | 40.05% |
| Profit Margin | 33.15% |
| EBITDA Margin | 27.31% |
| EBIT Margin | 11.92% |
| FCF Margin | n/a |
Dividends & Yields
This stock pays an annual dividend of 1.50, which amounts to a dividend yield of 2.25%.
| Dividend Per Share | 1.50 |
| Dividend Yield | 2.25% |
| Dividend Growth (YoY) | 20.00% |
| Years of Dividend Growth | 1 |
| Payout Ratio | 28.62% |
| Buyback Yield | -6.49% |
| Shareholder Yield | -4.24% |
| Earnings Yield | 6.55% |
| FCF Yield | -2.66% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on July 27, 2023. It was a forward split with a ratio of 1.125.
| Last Split Date | Jul 27, 2023 |
| Split Type | Forward |
| Split Ratio | 1.125 |
Scores
SCI Pharmtech has an Altman Z-Score of 4.96 and a Piotroski F-Score of 6.
| Altman Z-Score | 4.96 |
| Piotroski F-Score | 6 |